Premium
Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti‐allergen IgG can enhance the anaphylactic reaction
Author(s) -
Denépoux Stéphane,
Eibensteiner Petra B.,
Steinberger Peter,
Vrtala Susanne,
Visco Vincenzo,
Weyer Anne,
Kraft Dietrich,
Banchereau Jacques,
Valenta Rudolf,
Lebecque Serge
Publication year - 2000
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(99)01703-2
Subject(s) - allergen , immunoglobulin e , monoclonal antibody , immunotherapy , antibody , chemistry , desensitization (medicine) , immunology , antigen , microbiology and biotechnology , allergy , immune system , biology , biochemistry , receptor
We report the molecular characterization of five human monoclonal antibodies, BAB1–5 (BAB1: IgG 1 ; BAB4: IgG 2 ; BAB2, 3, 5: IgG 4 ), with specificity for the major birch pollen allergen, Bet v 1. BAB1–5 were obtained after immunotherapy and contained a high degree of somatic mutations indicative of an antigen‐driven affinity maturation process. While BAB1 inhibited the binding of patients IgE to Bet v 1, BAB2 increased IgE recognition of Bet v 1, and, even as Escherichia coli ‐expressed Fab, augmented Bet v 1‐induced immediate type skin reactions. The demonstration that IgG antibodies can enhance allergen‐induced allergic reactions is likely to explain the unpredictability of specific immunotherapy.